Explore Akero Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for AKRO. Akero Therapeutics, Brinker International And Viavi Are Among Top Mid ...

Rolph Timothy, the Chief Scientific Officer of Akero Therapeutics Inc . (NASDAQ:AKRO), recently executed a notable share sale, as per the latest SEC filing. The timing is particularly interesting ...

Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report)’s stock price gapped up before the market opened on Friday after an insider bought additional shares in the company. The stock had ...

Akero Therapeutics, Inc. (NASDAQ:AKRO) is a biotech company making treatments for metabolic diseases, particularly focusing on metabolic dysfunction-associated steatohepatitis (MASH).

A drug developed by US biotech Akero Therapeutics has hit the mark in a phase 2b trial in non-alcoholic steatohepatitis (NASH) – catapulting it to the forefront of efforts to find effective ...

H.C. Wainwright analyst Ed Arce raised the firm’s price target on Akero Therapeutics (AKRO) to $75 from $72 and keeps a Buy rating on the shares following the Q4 report. The firm expects EFX’s ...

Morgan Stanley analyst Michael Ulz lowered the firm’s price target on Akero Therapeutics (AKRO) to $90 from $96 and keeps an Overweight rating on the shares. The company’s Q4 report was ...

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company’s lead product ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.